

NCT ID	NCT05743036
Title	ZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2023-02-24
Location	California, United States Kansas, United States Texas, United States Australia Germany Hungary Italy Poland Spain
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, encorafenib, ZN-c3
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05759728
Title	A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2023-03-08
Location	Australia
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05714553
Title	NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase	Phase 1, Phase 2
Date Added	2023-02-06
Location	United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
Tags	MSI-H/ MMRd
NCT ID	NCT05426005
Title	Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2022-06-21
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Cadonilimab
Tags	MSI-H/ MMRd

NCT ID	NCT05653882
Title	A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Phase	Phase 1
Date Added	2022-12-16
Location	California, United States Connecticut, United States Florida, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Tennessee, United States Virginia, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05464030
Title	Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Phase	Phase 1
Date Added	2022-07-19
Location	California, United States Rhode Island, United States Texas, United States Canada Japan Korea, Republic of Spain
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	M9140
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05198934
Title	Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)
Phase	Phase 3
Date Added	2022-01-20

Location	Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia France Germany Greece Italy Japan Korea, Republic of Mexico Spain Taiwan United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05349890
Title	Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Phase	Phase 1
Date Added	2022-04-27
Location	Oregon, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	CDX-1140, Pembrolizumab, Keytruda
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05350917
Title	Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
Phase	Phase 2
Date Added	2022-04-28
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05409417
Title	Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
Phase	Phase 2
Date Added	2022-06-08

Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Unknown status
Drugs	Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX
Tags	MSS/ MMRp